Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare gene ...